# Satiogen Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/satiogen-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: http://bilarmscience.com/
- Total disclosed funding: $0.7M
- Latest round: Series A (Apr 15, 2008)
- Investors on record: 1

## About

Based in California, US, and founded in 2007, Satiogen Pharmaceuticals, Inc operates as a specialty pharma company that focuses on novel targets for treating type 2 diabetes and its metabolic mechanism therapy regulates nutrient intake and postprandial glucose. The company was Co-founded by Andrew Young and Bronislava Gedulin. In May 2022, Mirum Pharmaceuticals, Inc., a portfolio company of Deerfield Management, Frazier Healthcare Partners, and New Enterprise Associates acquired Satiogen Pharmaceuticals, Inc. from Mesa Verde Venture Partners.

The company offers treatment for type 2 diabetes through the bile acid brake concept. The "Bile Acid Brake" is a metabolic regulation system that reduces food intake and postprandial hyperglycemia when bile acids accumulate in the colon and rectum.  Bile acids bind to intraluminal G-protein coupled receptors on colorectal L-cells, which release a variety of metabolic hormones that regulate satiety and glucose homeostasis.

## Funding rounds

- Series A, Apr 15, 2008, $0.7M — Mesa Verde Venture Partners

## Investors

- Mesa Verde Venture Partners (https://capitalatlas.ai/funds/mesa-verde-venture-partners) — Series A